There are increasingly more bladder-sparing strategies for patients with even aggressive bladder cancer, said Alexander Kutikov, MD, FACS, chair, Department of Urology, Fox Chase Cancer Center.
With new treatments and better risk stratification, there is increasingly more opportunity for bladder-sparing strategies in bladder cancer, said Alexander Kutikov, MD, FACS, chair, Department of Urology, Fox Chase Cancer Center.
Transcript
What did you discuss in your session about organ preservation in patients with bladder cancer?
The best bladder is one's own, and what are the strategies in 2024 in actually saving one's bladder even when there's aggressive disease? We reviewed the state-of-the-art that is currently available, which is neoadjuvant chemotherapy and risk stratification and really predicting whether there is residual disease after chemotherapy and its challenges. For instance, there's a prospective trial1 that we did at the Fox Chase Cancer Center where we showed that that even though we would scrape the scar and do systematic biopsies and see nothing on endoscopic examination, about 25% of those patients harbored submucosal bladder cancer. And we talked about strategies of how to improve that prediction, but also discussed that if patients are appropriately stratified and appropriately counseled on the risks, there are opportunities to spare their bladders with or without delivering radiation to the bladder.
What advancements have we seen in bladder-sparing treatment?
The field has really been disrupted by enfortumab vedotin plus pembrolizumab data2 showing how remarkably superior those systemic therapy strategies are over cisplatin-based chemotherapy. This is in the metastatic setting, but now there are trials being done in the neoadjuvant setting [and] in the localized muscle-invasive setting. I think there's a lot of hope there that we can offer patients bladder-sparing approaches following systemic therapy, but that chapter is not yet written. The data are still not there, but clinically we're seeing incredible responses.
References
1. Zibelman M, Asghar AM, Parker DC. et al. Cystoscopy and systematic bladder tissue sampling in predicting pT0 bladder cancer: a prospective trial. J Urol. 2021;205(6):1605-1611. doi:10.1097/JU.0000000000001602
2. McNulty R. FDA approves enfortumab vedotin plus pembrolizumab for locally advanced or metastatic bladder cancer. The American Journal of Managed Care. December 18, 2023. Accessed May 7, 2024. https://www.ajmc.com/view/fda-approves-enfortumab-vedotin-plus-pembrolizumab-for-locally-advanced-or-metastatic-bladder-cancer
NGS-Based Test Accurately Detects Post–Allo-HSCT Relapse in AML, MDS
February 21st 2025The next-generation sequencing (NGS)–based AlloHeme test accurately predicted relapse following allogeneic hematopoietic stem cell transplantation (allo-HSCT) in acute myeloid leukemia (AML) and myelodysplastic syndromes (MDS).
Read More
Prostate Cancer Studies Show Why Personalized Treatment, Trial Diversity Matter, Dorff Says
February 21st 2025Tanya B. Dorff, MD, medical oncologist and professor in City of Hope’s Department of Medical Oncology & Therapeutics Research, was a discussant for the TALAPRO-2 and STOPCAP trials at the opening session of ASCO GU.
Read More
Politics vs Science: The Future of US Public Health
February 4th 2025On this episode of Managed Care Cast, we speak with Perry N. Halkitis, PhD, MS, MPH, dean of the Rutgers School of Public Health, on the public health implications of the US withdrawal from the World Health Organization and the role of public health leaders in advocating for science and health.
Listen
NSCLC Advancements Offer Hope, but Disparities Persist
February 20th 2025Ioana Bonta, MD, Georgia Cancer Specialists, discusses the evolving state of non-small cell lung cancer (NSCLC) treatments, their impact on patient outcomes, and the need to address ongoing disparities in these populations.
Read More
Abortion in 2025: Access, Fertility, and Infant Mortality Updates
February 20th 2025While Republican state-led efforts aim to increase restrictions to abortion care and access to mifepristone and misoprostol in 2025, JAMA authors join the conversation with their published research and commentary.
Read More